Bertek Nebivolol NDA Submission Could Yield Third Branded Antihypertensive
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Mylan’s branded drugs subsidiary Bertek is closer to adding a third hypertension drug to its product lineup with the submission of an NDA for the cardioselective beta blocker nebivolol. The firm thinks the agent could serve as the cornerstone of its branded business.
You may also be interested in...
Nebivolol Approval Could Come Before Extended User Fee Date Of May 31
Mylan nebivolol user fee date extended to May 31 after submission of additional analyses of already submitted data, firm says. Mylan had planned to use proposed merger partner King’s sales force for the beta blocker before the deal collapsed in eleventh hour. Mylan may seek another partner, but licensor J&J has last call
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product